ARROGENE
Arrogene is a developer of a cancer medical technology designed to create a new generation of nano agents capable of delivering peptide, protein, and oligonucleotide therapeutics across the blood-brain barrier. The company's technology offers a unique nano-medicine platform that delivers multiple tumor inhibitors or imaging agents and is being tailored to fight different types of cancer, enabling patients to prevent tumor growth for imaging.
ARROGENE
Industry:
Biotechnology Health Diagnostics
Founded:
2007-01-01
Address:
Santa Monica, California, United States
Country:
United States
Website Url:
http://www.arrogene.com
Total Employee:
1+
Status:
Active
Contact:
+1-424-238-4442
Email Addresses:
[email protected]
Total Funding:
7.9 M USD
Technology used in webpage:
Domain Not Resolving Euro Google Maps
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Applied StemCell
Applied StemCell is a biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics.
Lucira Health
Lucira Health is a biotechnology company that offers disposable test kits to detect RNA and DNA of infectious diseases.
Current Employees Featured
Founder
More informations about "Arrogene"
Arrogene Company Profile | Management and Employees List
Arrogene has licensed technologies and patents for its core technology-Polycefin™-from Cedars-Sinai Medical Center (CSMC) in Los Angeles, one of the nation's premiere research …See details»
Arrogene Company Profile - Office Locations, Competitors ... - Craft
Arrogene $3.75 m in total funding,. See insights on Arrogene including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Company Information - RocketReach
Arrogene, Inc., was founded in 2006, to commercialize both a new targeted cancer treatment technology and a proprietary molecular delivery platform aimed at inhibiting and ultimately …See details»
Arrogene - Overview, News & Similar companies | ZoomInfo.com
Who is Arrogene. Arrogene, Inc., was founded in 2006, to commercialize both a new targeted cancer treatment technology and a proprietary molecular delivery platform aimed at inhibiting …See details»
Arrogene Company Profile 2024: Valuation, Funding & Investors
Arrogene General Information Description. Developer of targeted cancer treatment technologies designed to inhibit tumor progression. The company's nanomedicine platform to delivers nano …See details»
Arrogene - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Arrogene, Inc. in Los Angeles CA - Company Profile - Corporation …
Arrogene, Inc. Overview. Arrogene, Inc. filed as a Statement & Designation By Foreign Corporation in the State of California on Wednesday, June 7, 2017 and is approximately six …See details»
Arrogene, Inc. Overview | SignalHire Company Profile
Summary. Arrogene, Inc. is a research company based out of 8560 W SUNSET BLVD, Los Angeles, California, United States. Organization WebsiteSee details»
Arrogene - Crunchbase
Arrogene is a development stage company that develops nano-biopolymers and related technologies for cancer therapeutics and diagnostics. Search Crunchbase. Start Free Trial . …See details»
Arrogene, Inc. - CMOCRO
Arrogene was founded to commercialize both a new targeted cancer treatment technology and a proprietary molecular delivery platform that interferes with those targets in order to inhibit and …See details»
Arrogene - Company Profile - Tracxn
Aug 15, 2024 Arrogene ranks 1,451st among 2688 active competitors. 946 of its competitors are funded while 587 have exited. Overall, Arrogene and its competitors have raised over $81.7B …See details»
ARROGENE INC Company Profile | Los Angeles, CA | Competitors ...
ARROGENE INC. Website. Get a D&B Hoovers Free Trial. Overview Company Description:? Key Principal: LARRY COUTURE See more contacts Industry: Scientific Research and …See details»
EIN 20-8057585 - Arrogene, Inc, Los Angeles, California - EIN TaxId
Arrogene, Inc is a corporation in Los Angeles, California. The employer identification number (EIN) for Arrogene, Inc is 208057585. EIN for organizations is sometimes also referred to as …See details»
Arrogene, Inc.:Company Profile & Technical Research,Competitor …
Arrogene, Inc. is a company that provides Cancer, Medicine, Drug and more. Arrogene, Inc. is headquartered in United States California. Arrogene, Inc. was founded in 2007. Arrogene, Inc. …See details»
Arrogene Inc Company Profile | Tarzana, CA - Dun & Bradstreet
Arrogene Inc. Website. Get a D&B Hoovers Free Trial. Overview Company Description:? Key Principal: Juliet Ljubimova See more contacts Industry: Nonclassifiable establishments. Printer …See details»
Arrogene Inc Overview - Salary.com
Arrogene Inc Information BETA. Headquarters Address: 12100 Wilshire Blvd Ste 800, Los Angeles, California. Phone Number: +1 4242384442. Revenue: $1 Million - $5 Million ... The …See details»
Arrogene - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Arrogene . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. About. Arrogene has 4 …See details»
Arrogene - Products, Competitors, Financials, Employees, …
When was Arrogene founded? Arrogene was founded in 2006. Where is Arrogene's headquarters? Arrogene's headquarters is located at 8560 West Sunset Boulevard, Los …See details»
Arrogene - Raised $9.19M Funding from 1 investor - Tracxn
Oct 16, 2024 Arrogene raised an undisclosed amount in its latest funding round, which was Series A round held on Oct 30, 2019. How much funding has Arrogene raised till date? …See details»
Stellantis CEO Carlos Tavares lost control of the automaker with ...
1 day ago Sources told CNBC that Carlos Tavares was fixated on near-term costs and profits to the detriment of the business as well as the company's products.See details»